Related Experiment Video

Updated: Aug 16, 2025

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.4K

Isorhamnetin inhibits progression of ovarian cancer by targeting ESR1

Manman Wang1, Zhengtan Xu1, Qi Cai1

  • 1Department of Pharmacy, West China Hospital of Sichuan University, Chengdu, China.

Annals of Translational Medicine
|December 22, 2022
PubMed
Abstract

Insights

Isorhamnetin (ISO) inhibits ovarian cancer (OC) cell proliferation, migration, and invasion by targeting estrogen receptor 1 (ESR1). This study provides a basis for further research into ISO as an OC treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Herbal Medicine

Background:

  • Ovarian cancer (OC) treatment often involves Chinese herbal medicine, but the specific role of isorhamnetin (ISO) is unclear.
  • Isorhamnetin (ISO) is a flavonol with known immune, anti-inflammatory, and anticancer properties.
  • This study investigates the potential of ISO in ovarian cancer (OC) treatment using network pharmacology.

Purpose of the Study:

  • To explore the therapeutic targets of isorhamnetin (ISO) in ovarian cancer (OC) using network pharmacology.
  • To identify the correlation between target gene expression and patient survival.
  • To elucidate the mechanism of ISO action in OC, focusing on estrogen receptor 1 (ESR1).

Main Methods:

  • Network pharmacology was employed to screen for common targets of ISO in OC.
  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed.
  • Protein-protein interaction networks were constructed, and gene expression correlations with survival were analyzed using UALCAN. In vitro and in vivo experiments assessed ISO's effects on OC cells and ESR1 function.

Main Results:

  • Network pharmacology identified 25 target genes for ISO in OC treatment.
  • High ESR1 expression significantly correlated with overall survival in OC patients.
  • ISO inhibited OC cell proliferation, migration, and invasion in vitro and in vivo. ESR1 overexpression promoted these processes and reversed ISO's inhibitory effects.

Conclusions:

  • Isorhamnetin (ISO) effectively inhibits ovarian cancer (OC) cell proliferation, migration, and invasion.
  • The mechanism involves targeting estrogen receptor 1 (ESR1) expression.
  • These findings provide a theoretical foundation for the pharmacological application of ISO in OC treatment.
Keywords:
Estrogen receptor 1 (ESR1)isorhamnetin (ISO)network pharmacologyovarian cancer (OC)proliferation

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K